Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.05.10.21256192: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The trial was approved by the Federal Authority Paul-Ehrlich-Institute and by the Ethical Committee of the University of Ulm and the ethical committees of the participating hospitals.
Consent: Written informed consent was obtained from all study participants or their legal representatives.Sex as a biological variable not detected. Randomization Design: This is a multicenter, open-label randomized clinical trial to evaluate the efficacy and safety of CCP added to standard therapy (CCP group) vs. standard therapy alone (control group) in hospitalized patients with COVID-19 (Figure 1). Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Al… SciScore for 10.1101/2021.05.10.21256192: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The trial was approved by the Federal Authority Paul-Ehrlich-Institute and by the Ethical Committee of the University of Ulm and the ethical committees of the participating hospitals.
Consent: Written informed consent was obtained from all study participants or their legal representatives.Sex as a biological variable not detected. Randomization Design: This is a multicenter, open-label randomized clinical trial to evaluate the efficacy and safety of CCP added to standard therapy (CCP group) vs. standard therapy alone (control group) in hospitalized patients with COVID-19 (Figure 1). Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources All statistical analyses were performed according to the statistical analysis plan using SAS® (version 9.4M6 or newer, www.sas.com). SAS®suggested: (SASqPCR, RRID:SCR_003056)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04433910 Completed A Clinical Trial of Convalescent Plasma Compared to Best Sup… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
